New drug LP-005 passes first safety check in healthy volunteers
NCT ID NCT06294301
First seen Jan 11, 2026 · Last updated May 13, 2026 · Updated 16 times
Summary
This early-stage study tested LP-005, a potential treatment for a rare blood disease called PNH, in 68 healthy adults aged 18 to 50. The main goal was to check safety and how the drug moves through the body. Participants received either a single or multiple doses of LP-005, and researchers monitored side effects and drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, PNH are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Public Health Clinical Center
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.